This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
suffer from heartfailure , and there are approximately 400,000 heart-failure-related deaths in this country each year. Patients with heartfailure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden.
It is also published in Heart Rhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS. Prolonged anticoagulation may be required depending on the risk of bloodclots.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
Early treatment of persistent AF can reduce the risk of bloodclots, stroke, and heartfailure, and may prevent the disease from becoming permanent. Patients are often treated with AADs as frontline therapy for heart rhythm maintenance, though some can experience adverse effects and limited efficacy.
If untreated, AFib can lead to or exacerbate heartfailure, and it significantly increases a person’s risk of stroke. Catheter ablation was given the highest Class 1 treatment recommendation for appropriately selected patients, including those with heartfailure with reduced ejection fraction.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content